共 9 条
- [1] Transmitter deficits in Alzheimer’s disease. Hardy J,Adolfsso R,Alafuzof I. Neurochemistry International . 1985
- [2] Drag evaluation of huperzine A in the treatment of senile memory disorders. Zhang RW,Tang XC,Plan YY,Sang GW,Zhang YD,Ma YX,et al. Acta Pharmacological Sinica . 1991
- [3] Effects of huperzine A and B on skeletal muscle and electroencephalogram. Yan XF,Lu WH,Lou WJ,"Fang XC. Acta Pharmacological Sinica . 1987
- [4] A 30-week randomized controlled trial of high-dose tacrine in patiens with Alzheimer’s disease. Knapp MJ,Knopman DS,Solomon PR,Pendleberg WW,Davis CS,Gracon SI. The Journal of The American Medical Association . 1994
- [5] Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Chatellier G,Lacomblez L. British Medical Journal . 1990
- [6] Effects of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Xiong ZQ,Tang XC. Pharmacol Biochem Behav . 1995
- [7] Anti-cholinesterase activity of huperzine A. Wang YE,Yue DX,Tang XC. Acta Pharmacological Sinica . 1986
- [8] Drug treatments of dementia. Whalley LJ. British Journal of Psychiatry . 1989
- [9] The structure of huperzine A and B, two new alkaloids exhibiting marked anti-cholinesterase activity. Liu JS,Zhu YL,Yu CM,Zhou YZ,Han YY,Wu FW,et al. Canadian Journal of Chemistry . 1986